Literature DB >> 19639506

Expression of the cellular oxygen sensor PHD2 (EGLN-1) predicts radiation sensitivity in squamous cell cancer of the head and neck.

Marjaana Luukkaa1, Terhi Jokilehto, Pauliina Kronqvist, Tero Vahlberg, Reidar Grénman, Panu Jaakkola, Heikki Minn.   

Abstract

PURPOSE: Prolyl hydroxylase domain proteins constitute a family of oxygen sensors that regulate the expression of hypoxia-inducible factor-1 alpha (HIF-1alpha), which mediates transcription of many genes under low oxygen concentration. PHD2 (Prolyl hydroxylase domain protein 2) isoform is the main regulator of HIF-1alpha degradation in normoxia and mild hypoxia. The aim of our study was to evaluate the relationship between expression of PHD2 and radiosensitivity in squamous cell cancer of the head and neck (HNSCC). PATIENTS AND METHODS: Paraffin embedded sections from untreated primary tumours were obtained for immunohistochemistry in 48 HNSCC patients scheduled for preoperative radiotherapy (RT). Nuclear expression of PHD2 was evaluated as a percentage of tumour cells showing positively stained nucleus. RT was a split-course accelerated hyperfractionated regimen (1.6 Gy twice a day) in 15 patients and standard in 33 patients. Viability of cancer cells was routinely evaluated histologically from resected tumours at planned surgery 3-4 weeks after RT. The follow-up time after multimodality treatment was five years or until death.
RESULTS: PHD2 expression was low in normal tissues and well differentiated tumours. The expression was increased and predominantly nuclear in poorly differentiated tumours. In tumours later found to be sterilised by RT, nuclear PHD2 expression was markedly lower as compared to tumours showing viable cells at surgery (p = 0.04). A low nuclear staining of PHD2 (<10% of PHD2-positive nuclei) in the primary tumour was found to associate with good radiation response (p = 0.005).
CONCLUSIONS: We found low PHD2 expression and in particular low nuclear expression to predict a favourable response to RT. Therefore, nuclear PHD2 expression may act as a surrogate marker for radiation resistance in HNSCC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19639506     DOI: 10.1080/09553000903074104

Source DB:  PubMed          Journal:  Int J Radiat Biol        ISSN: 0955-3002            Impact factor:   2.694


  7 in total

Review 1.  Nuclear-cytoplasmatic shuttling of proteins in control of cellular oxygen sensing.

Authors:  Reinhard Depping; Wolfgang Jelkmann; Friederike Katharina Kosyna
Journal:  J Mol Med (Berl)       Date:  2015-03-27       Impact factor: 4.599

2.  EGLN1 involvement in high-altitude adaptation revealed through genetic analysis of extreme constitution types defined in Ayurveda.

Authors:  Shilpi Aggarwal; Sapna Negi; Pankaj Jha; Prashant K Singh; Tsering Stobdan; M A Qadar Pasha; Saurabh Ghosh; Anurag Agrawal; Bhavana Prasher; Mitali Mukerji
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-18       Impact factor: 11.205

Review 3.  The multifaceted role of EGLN family prolyl hydroxylases in cancer: going beyond HIF regulation.

Authors:  Silvia Strocchi; Francesca Reggiani; Giulia Gobbi; Alessia Ciarrocchi; Valentina Sancisi
Journal:  Oncogene       Date:  2022-06-15       Impact factor: 8.756

4.  A Genetically Encoded FRET Sensor for Hypoxia and Prolyl Hydroxylases.

Authors:  Suzan Youssef; Wei Ren; Hui-Wang Ai
Journal:  ACS Chem Biol       Date:  2016-07-14       Impact factor: 5.100

5.  The Nuclear Export Inhibitor Selinexor Inhibits Hypoxia Signaling Pathways And 3D Spheroid Growth Of Cancer Cells.

Authors:  Reinhard Depping; Moritz von Fallois; Yosef Landesman; Friederike Katharina Kosyna
Journal:  Onco Targets Ther       Date:  2019-10-11       Impact factor: 4.147

Review 6.  The role of HIF prolyl hydroxylases in tumour growth.

Authors:  Terhi Jokilehto; Panu M Jaakkola
Journal:  J Cell Mol Med       Date:  2010-02-22       Impact factor: 5.310

7.  EGLN1 induces tumorigenesis and radioresistance in nasopharyngeal carcinoma by promoting ubiquitination of p53 in a hydroxylase-dependent manner.

Authors:  Lu Sun; Cheng Wu; Jun Ming; Ergang Guo; Wei Zhang; Lingling Li; Guoqing Hu
Journal:  J Cancer       Date:  2022-03-28       Impact factor: 4.478

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.